Gland Pharma Limited (NSE:GLAND)
India · Delayed Price · Currency is INR | Market Cap | 276.89B |
| Revenue (ttm) | 58.01B |
| Net Income (ttm) | 7.90B |
| Shares Out | 164.76M |
| EPS (ttm) | 47.98 |
| PE Ratio | 35.03 |
| Forward PE | 27.08 |
| Dividend | 18.00 (1.07%) |
| Ex-Dividend Date | Aug 14, 2025 |
| Volume | 93,457 |
| Average Volume | 137,470 |
| Open | 1,700.00 |
| Previous Close | 1,694.80 |
| Day's Range | 1,672.30 - 1,700.00 |
| 52-Week Range | 1,277.80 - 2,131.00 |
| Beta | 0.36 |
| RSI | 42.81 |
| Earnings Date | Jan 28, 2026 |
About Gland Pharma
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neopla... [Read more]
Financial Performance
In 2024, Gland Pharma's revenue was 56.17 billion, a decrease of -0.85% compared to the previous year's 56.65 billion. Earnings were 6.99 billion, a decrease of -9.57%.
Financial StatementsNews
Gland Pharma shares surge nearly 4% after getting USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC)
Gland Pharma shares climbed nearly 4% after the company announced that it has received approval from the United States Food...
Top stocks to watch today, January 8: Infosys, Tata Steel, HUDCO, Gland Pharma, Angel One, Cipla and more
Indian equity markets are likely to begin Thursday’s session on a cautious note. Trends from global indices and GIFT Nifty...
Gland Pharma receives USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC)
Gland Pharma Limited, a leading injectable and ophthalmic-focused pharmaceutical company, has received approval from the United States Food and Drug...
Nomura cautious on Gland Pharma, trims estimates post Q2 miss but sees long-term visibility
Nomura has maintained its neutral rating on Gland Pharma with a target price of ₹2,000 per share after the company...
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
Q2 2026 Gland Pharma Ltd Earnings Call Transcript
Q2 2026 Gland Pharma Ltd Earnings Call Transcript
Gland Pharma Q2 Results: Revenue jumps 5.8% YoY to Rs 1,487 crore, net profit up 12.2%
Gland Pharma reported a steady performance in the September quarter (Q2 FY26), with moderate year-on-year growth across key financial metrics....
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Report Preview: What To Expect
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Report Preview: What To Expect
These Indian pharma stocks tumble as Trump announces 100% tariff on branded drugs
Indian pharmaceutical shares came under heavy selling pressure on Friday, September 26, after U.S. President Donald Trump announced a 100% tariff on branded and patented pharmaceutical drugs starting ...
Gland Pharma shares fall over 4% as Trump announces 100% tariff on pharma imports
Shares of Gland Pharma slipped 4.03% to ₹1,892.50 in Friday’s session, as investors reacted sharply to U.S. President Donald Trump’s announcement of a 100% tariff on imports of branded and patented ph...
Gland Pharma down 4%, Sun Pharma slips 2.6%, Dr Reddy’s down 2%, Zydus nearly 3%, Aurobindo down 2% as Trump’s 100% pharma tariff jolts sector
Indian pharmaceutical stocks came under heavy selling pressure on Friday, September 26, after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented pharmaceutical drug...
Gland Pharma gets USFDA nod for Vasopressin in 5% Dextrose RTU Injection
Gland Pharma Limited, a Hyderabad-based generic injectable and ophthalmic-focused pharmaceutical company, announced that it has received approval from the United States Food and Drug Administration (U...
Gland Pharma gets USFDA approval for Cangrelor injection with 180-day exclusivity
Gland Pharma Limited, a leading player in the generic injectable and ophthalmic pharmaceutical space, has received the green light from the United States Food and Drug Administration (USFDA) for its A...
Gland Pharma shares jump 4% as Q1 revenue rises 7% YoY to Rs 1,505.6 crore, net profit up 50% YoY
Gland Pharma shares climbed over 4% in early trade on Wednesday after the company reported strong financial results for the first quarter of FY26. The pharmaceutical major delivered robust growth acro...
Top stocks to watch today, August 6: Bharti Airtel, Lupin, Britannia, NCC, Gland Pharma and more
The Indian stock market is likely to see stock-specific action today, August 6, as several companies have announced their Q1 earnings, signed key deals, or received regulatory clearances. Here’s a qui...
Gland Pharma share: Jefferies upgrades to hold, Goldman Sachs maintains sell; divergent views on recovery and upside
Jefferies has upgraded its rating on Gland Pharma to Hold from its previous stance, with a revised target price of ₹1,970, citing operational recovery signs and a turnaround in its European subsidiary...
Gland Pharma Q1 Results: Revenue surges 7% YoY to Rs 1,505.6 crore, net profit up 50% YoY
Gland Pharma posted a robust set of Q1 FY26 results, showcasing significant year-on-year growth across revenue, margins, and profitability. The company’s revenue from operations stood at ₹1,505.6 cror...
Gland Pharma gets GMP certification for Pashamylaram facility from Danish Medicines Agency
Gland Pharma has announced that its Pashamylaram facility has received a Good Manufacturing Practices (GMP) Compliance Certificate from the Danish Medicines Agency. This certification is crucial for m...
Gland Pharma gets EIR from US FDA for Visakhapatnam JNPC facility
Gland Pharma has announced that it has received the Establishment Inspection Report (EIR) from the US FDA for its sterile API manufacturing facility located at JNPC, Visakhapatnam. This follows the su...
Top stocks to buy today: Stock recommendations for June 19, 2025 - check list
Top stock market recommendations: Aakash K Hindocha from Nuvama Professional Clients Group recommends Kaynes, Mahanagar Gas Limited (MGL), and Gland Pharma as top stock picks for today. Nifty is expec...
Top stocks to watch today, June 5: Gland Pharma, HAL, Newgen Software, NTPC Green, Angel One and more
Benchmark stock indices Sensex and Nifty ended higher on Wednesday, June 4, 2025, after three consecutive sessions of losses, supported by gains in global markets. The BSE Sensex rose 260.74 points, o...
Gland Pharma gets USFDA nod for Angiotensin II Acetate Injection, secures 180-day exclusivity
Gland Pharma Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection, 2.5 m...
Gland Pharma shares rise over 3% following Q4 Results
Shares of Gland Pharma Ltd surged 3.34% to ₹1,548.30 on Wednesday, following the company’s Q4 FY25 results. Despite a decline in profit and sales, investor sentiment remained upbeat, possibly buoyed b...
Gland Pharma share price: Nomura sees 4% upside, maintains neutral on soft Q4 and cautious outlook
Nomura has maintained its neutral stance on Gland Pharma with a target price of ₹1,570, reflecting a modest upside of 4% from the current market price of ₹1,503.90. The cautious view follows a mixed Q...
Brokerage radar: Hindalco, BEL, Dixon, Zydus, Gland Pharma in focus after Q4; target prices revised
Top brokerages including CLSA, Morgan Stanley, Nomura and Nuvama have released fresh commentary on several Indian stocks following their Q4FY25 results. The reports highlight key upgrades, revised tar...